Acipimox

Acipimox

SCHEMBL48922

Cc1cnc(C(=O)O)c[n+]1[O-]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 4/20 1.00
P4HTM Q9NXG6 10/20 0.38
P4HA1 P13674 1/20 0.38
MIF P14174 1/20 0.38
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
MAPK1 P28482 1/20 0.36
NAPRT Q6XQN6 1/20 0.35
ASPH Q12797 2/20 0.35
KDM8 Q8N371 1/20 0.35
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
PKM P14618 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
NFKB1 P19838 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acipimox SCHEMBL29370131 1.00 HCAR2 (1.00) HCAR2P4HTMP4HA1MIFKDM4E
Acipimox SCHEMBL6057382 1.00 HCAR2 (1.00) HCAR2P4HTMP4HA1MIFKDM4E
Acipimox SCHEMBL28690337 0.98 HCAR2 (0.96) HCAR2P4HTMP4HA1MIFKDM4E
Acipimox SCHEMBL28681646 0.98 HCAR2 (0.96) HCAR2P4HTMP4HA1MIFKDM4E
Acipimox SCHEMBL28986974 0.98 HCAR2 (0.96) HCAR2P4HTMP4HA1MIFKDM4E
Acipimox SCHEMBL31290731 0.98 HCAR2 (0.96) HCAR2P4HTMP4HA1MIFKDM4E
Acipimox SCHEMBL28273592 0.98 HCAR2 (0.96) HCAR2P4HTMP4HA1MIFKDM4E
Acipimox SCHEMBL11743417 0.89 HCAR2 (0.79) HCAR2P4HTMP4HA1MIFKDM4E
Acipimox SCHEMBL28438037 0.87 HCAR2 (0.77) HCAR2P4HTMP4HA1MIFKDM4E
Acipimox SCHEMBL22409661 0.85 HCAR2 (0.72) HCAR2P4HTMKDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7760 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2026-03-26 US claimed
US-20260076956-A1 METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF US GOV VETERANS AFFAIRS (US) 2026-03-19 US claimed
WO-2025264604-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME THE PROCTER & GAMBLE COMPANY (US) 2025-12-26 WO claimed
US-20250381110-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME PROCTER & GAMBLE (US) 2025-12-18 US claimed
EP-4612132-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS Sitryx Therapeutics Limited (GB) 2025-09-10 EP claimed
EP-4583916-A2 COMPOSITIONS AND METHODS FOR AMELIORATION OF SYMPTOMS ASSOCIATED WITH CLEC16A DYSFUNCTION OR LOSS The Children's Hospital Of Philadelphia (US) 2025-07-16 EP claimed
CN-120166987-A Phthalazine derivatives as pyruvate kinase modulators 西特瑞治疗有限公司 2025-06-17 CN claimed
CN-120114405-A Acipimox capsule and preparation method thereof 鲁南贝特制药有限公司 2025-06-10 CN claimed
CN-120037248-A Medicament for simultaneously reducing bleeding and microvascular obstruction risks 中国科学院上海药物研究所 2025-05-27 CN claimed
US-12280047-B2 Treatment of aneurysms GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2025-04-22 US claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2001000184-A2 COMBINATION OF MTP INHIBITORS AND LIPID REDUCERS AND THE USE THEREOF IN MEDICAMENTS BAYER AKTIENGESELLSCHAFT (DE) 2001-01-04 WO claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
WO-2000038729-A1 COMBINATIONS OF ILEAL BILE ACID TRANSPORT INHIBITORS AND NICOTINIC ACID DERIVATIVES FOR CARDIOVASCULAR INDICATIONS G.D. SEARLE LLC (US) 2000-07-06 WO claimed
WO-2000038721-A1 COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND NICOTINIC ACID DERIVATIVES FOR CARDIOVASCULAR INDICATIONS G.D. SEARLE LLC (US) 2000-07-06 WO claimed
WO-1998022114-A1 A METHOD FOR PROMOTING TISSUE REPAIR DUMEX-ALPHARMA A/S (DK) 1998-05-28 WO claimed
US-5668117-A NERVOUS SYSTEM DISORDERS USING AROMATIC ACID COMPOUNDS SECANT PHARMA, LLC 1997-09-16 US claimed
US-5260305-A Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination E. R. SQUIBB & SONS, INC. (US) 1993-11-09 US claimed
US-5179097-A Salts of non-steroidal anti-inflammatory carboxylic acids and anti-lipidemic carboxylic acids ANGRES ISAAC A (US) 1993-01-12 US claimed
US-4002750-A HYPOGLYCEMIC AND HYPOLIPEMIC AGENTS CARLO ERBA S.P.A. (IT) 1977-01-11 US claimed